| Abstract | Cutaneous sarcoidosis may be a chronic disease with important morbidity requiring aggressive therapy. The efficacy of different anti-tumor necrosis factor alpha(anti-TNF-alpha) treatments in refractory cutaneous and systemic sarcoidosis has been reported previously. We report the first patient with chronic cutaneous sarcoidosis who responded to dose escalation of anti-TNF-alpha agents that have been ineffective at the standard dosage, illustrating that the optimal dosing regimen has still to be defined for this indication before considering difficult-to-treat patients as nonresponders. Our case report also illustrates that the fusion protein etanercept, even used at a high dosage, may be less effective for the treatment of cutaneous sarcoidosis than the monoclonal antibodies infliximab and adalimumab. |
| Authors | A-M Thielen, C Barde, J-H Saurat, E Laffitte
(Affiliation: Dermatology Department, Hôpitaux Universitaires de Genève, Geneva, Switzerland. anne-marie.thielen at hcuge.ch)
|
| Journal | Dermatology (Basel, Switzerland)
(Dermatology)
Vol. 219
Issue 1
Pg. 59-62
( 2009)
ISSN: 1421-9832 [Electronic] Switzerland |
| PMID | 19468200
(Publication Type: Case Reports, Journal Article)
|
| Copyright | 2009 S. Karger AG, Basel. |
| Chemical References |
- Antibodies, Monoclonal
- Tumor Necrosis Factor-alpha
- adalimumab
- infliximab
|
| Topics |
- Adult
- Antibodies, Monoclonal
(administration & dosage)
- Chronic Disease
- Female
- Humans
- Sarcoidosis
(drug therapy)
- Skin Diseases
(drug therapy)
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors)
|
